Tempus AI (TEM) and Recursion Pharmaceuticals (RXRX) extended their data license agreement through November 2029 and revised the contract's fee structure. Up to $84 million in dis ...

Recursion Pharmaceuticals (NASDAQ:RXRX) outlined its strategy, clinical pipeline and partnership progress at Morgan Stanley’s ...

Tempus AI, Inc. (NASDAQ: TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). Additionally, the two companies have entered into a new ...

Recursion Pharmaceuticals (RXRX) closed at $3.18 in the latest trading session, marking a -1.85% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 0.45% for the ...

Don't catch a falling knife.

September 11, 2026 16:26 ET Consumer prices data was the main news on the economic front in the U.S. this week. In Europe, ...

Recursion Pharmaceuticals shares have been a disaster for investors who've been holding them. After falling by more than half in less than a year, though, the stock could be a bargain now. Here's a ...

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However ...

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.16, moving -1.71% from the previous trading session. The stock's performance was behind the S&P 500's daily loss of 0.59%.